Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;100:2462-2463

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vale, P. R.
Right arrow Articles by Isner, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vale, P. R.
Right arrow Articles by Isner, J. M.

(Circulation. 1999;100:2462.)
© 1999 American Heart Association, Inc.


Images in Cardiovascular Medicine

Percutaneous Myocardial Gene Transfer of phVEGF-2

Peter R. Vale, MD; Douglas W. Losordo, MD; Charles E. Milliken, MS; Darryl D. Esakof, MD; Jeffrey M. Isner, MD

From the Departments of Medicine and Cardiovascular Research, St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Mass.

Correspondence to Jeffrey M. Isner, MD, St Elizabeth’s Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail jisner@opal.tufts.com

Gene transfer of phVEGF-2, an endothelial cell mitogen previously shown to promote angiogenesis in preclinical animal studies, is intended to promote collateral vessel development to the ischemic lateral LV wall. The strategy of gene delivery used in this case is designed to exploit the fact that muscle, particularly myocardium, yields relatively higher levels of gene expression than other tissue types; electromechanical mapping was used in this case to guide injection to sites of myocardial ischemia, because ischemic muscle yields even higher levels of gene expression. The patient was an 82-year-old man with coronary heart disease, including an old anteroseptal myocardial infarction (MI), previous coronary artery bypass surgery, and chronic angina refractory to medical therapy.



View larger version (42K):
[in this window]
[in a new window]
 
Figure 1. Percutaneous myocardial gene transfer of phVEGF-2. Panels of this composite figure depict various aspects of first human application of percutaneous myocardial gene transfer. A, Electromechanical (NOGA) map pair of left ventricle (LV) in left lateral view obtained with an endocardial mapping catheter. Color-coded voltage map on left shows that myocardial viability of lateral LV wall is preserved; linear local shortening map on right, however, shows that mechanical function of basal portion of lateral wall (red-orange) is impaired. Map pair thus suggests area of hibernating myocardium. B, Apical 2-chamber view from transthoracic echocardiogram showing thinning of ventricular septum (VS) (arrow) and apex of LV due to old MI. These sites would thus not be appropriate for gene transfer. C, Photograph of modified mapping-injection catheter (Biosense, Johnson & Johnson). Electrode at distal catheter tip allows annotation of electromechanical . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
HypertensionHome page
R. Morishita, M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. Matsuda, Y. Kaneda, and T. Ogihara
Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease
Hypertension, August 1, 2004; 44(2): 203 - 209.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. W. Losordo and S. Dimmeler
Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines
Circulation, June 1, 2004; 109(21): 2487 - 2491.
[Full Text] [PDF]


Home page
Eur Heart JHome page
C. Mannheimer, P. Camici, M.R. Chester, A. Collins, M. DeJongste, T. Eliasson, F. Follath, I. Hellemans, J. Herlitz, T. Luscher, et al.
The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina
Eur. Heart J., March 1, 2002; 23(5): 355 - 370.
[Full Text] [PDF]


Home page
CirculationHome page
C. Patterson and M. S. Runge
Therapeutic Myocardial Angiogenesis Via Vascular Endothelial Growth Factor Gene Therapy : Moving on Down the Road
Circulation, August 29, 2000; 102(9): 940 - 942.
[Full Text] [PDF]


Home page
CirculationHome page
P. R. Vale, D. W. Losordo, C. E. Milliken, M. Maysky, D. D. Esakof, J. F. Symes, and J. M. Isner
Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia
Circulation, August 29, 2000; 102(9): 965 - 974.
[Abstract] [Full Text] [PDF]